The Neuropsychiatric Manifestations of COVID-19: Interactions with Psychiatric Illness and Pharmacological Treatment

Overview

Journal Biomed Pharmacother

Specialties Biology
General Medicine
Pharmacology

Date 2021 Jan 9

PMID 33421734

Citations 41

Authors

Esme Jansen Van Vuren

Stephan F Steyn

Christiaan B Brink

Marisa Moller

Francois P Viljoen

Brian H Harvey

Affiliations

Soon will be listed here.

Abstract

The recent outbreak of the corona virus disease (COVID-19) has had major global impact. The relationship between severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection and psychiatric diseases is of great concern, with an evident link between corona virus infections and various central and peripheral nervous system manifestations. Unmitigated neuro-inflammation has been noted to underlie not only the severe respiratory complications of the disease but is also present in a range of neuro-psychiatric illnesses. Several neurological and psychiatric disorders are characterized by immune-inflammatory states, while treatments for these disorders have distinct anti-inflammatory properties and effects. With inflammation being a common contributing factor in SARS-CoV-2, as well as psychiatric disorders, treatment of either condition may affect disease progression of the other or alter response to pharmacological treatment. In this review, we elucidate how viral infections could affect pre-existing psychiatric conditions and how pharmacological treatments of these conditions may affect overall progress and outcome in the treatment of SARS-CoV-2. We address whether any treatment-induced benefits and potential adverse effects may ultimately affect the overall treatment approach, considering the underlying dysregulated neuro-inflammatory processes and potential drug interactions. Finally, we suggest adjunctive treatment options for SARS-CoV-2-associated neuro-psychiatric symptoms.

Citing Articles

Acute Schizophrenia-like Psychotic Disorder Against the Background of COVID-19.

Bravve L, Kaydan M, Kostyuk G Medicina (Kaunas). 2025; 61(2).

PMID: 40005415 PMC: 11857278. DOI: 10.3390/medicina61020298.

COVID-19 in patients with severe mental illness: An analysis of in-patients at a psychiatric hospital in Cape Town.

Sablay H, Cossie Q, Pieterse D S Afr J Psychiatr. 2025; 31:2286.

PMID: 39968316 PMC: 11830877. DOI: 10.4102/sajpsychiatry.v31i0.2286.

Investigating the Role of Serotonin Levels in Cognitive Impairments Associated with Long COVID-19.

Eslami Z, Joshaghani H Chonnam Med J. 2024; 60(3):141-146.

PMID: 39381125 PMC: 11458317. DOI: 10.4068/cmj.2024.60.3.141.

COVID-19 and Mental Health: A "Pandemic Within a Pandemic".

Fisicaro F, Lanza G, Concerto C, Rodolico A, Di Napoli M, Mansueto G Adv Exp Med Biol. 2024; 1458:1-18.

PMID: 39102186 DOI: 10.1007/978-3-031-61943-4_1.

A Comprehensive Review on Navigating the Neurological Landscape of COVID-19: Insights Into Etiopathogenesis and Clinical Management.

Chavhan R, Wanjari A, Kumar S, Acharya S, Rathod N, Reddy H Cureus. 2024; 16(5):e60079.

PMID: 38860093 PMC: 11163389. DOI: 10.7759/cureus.60079.

References

Alamdari D, Bagheri Moghaddam A, Amini S, Keramati M, Zarmehri A, Alamdari A . Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. Eur J Pharmacol. 2020; 885:173494. PMC: 7440159. DOI: 10.1016/j.ejphar.2020.173494. View

Xia H, Lazartigues E . Angiotensin-converting enzyme 2 in the brain: properties and future directions. J Neurochem. 2008; 107(6):1482-94. PMC: 2667944. DOI: 10.1111/j.1471-4159.2008.05723.x. View

Delaney S, Fallon B, Alaedini A, Yolken R, Indart A, Feng T . Inflammatory biomarkers in psychosis and clinical high risk populations. Schizophr Res. 2018; 206:440-443. DOI: 10.1016/j.schres.2018.10.017. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Rafiee L, Hajhashemi V, Javanmard S . Fluvoxamine inhibits some inflammatory genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat. Iran J Basic Med Sci. 2016; 19(9):977-984. PMC: 5080428. View

Xue F, Xue S, Liu L, Sang H, Ma Q, Tan Q . Early intervention with electroacupuncture prevents PTSD-like behaviors in rats through enhancing hippocampal endocannabinoid signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2019; 93:171-181. DOI: 10.1016/j.pnpbp.2019.03.018. View

Ettman C, Abdalla S, Cohen G, Sampson L, Vivier P, Galea S . Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. JAMA Netw Open. 2020; 3(9):e2019686. PMC: 7489837. DOI: 10.1001/jamanetworkopen.2020.19686. View

Moller M, du Preez J, Viljoen F, Berk M, Emsley R, Harvey B . Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. Brain Behav Immun. 2012; 30:156-67. DOI: 10.1016/j.bbi.2012.12.011. View

Zimniak M, Kirschner L, Hilpert H, Geiger N, Danov O, Oberwinkler H . The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue. Sci Rep. 2021; 11(1):5890. PMC: 7961020. DOI: 10.1038/s41598-021-85049-0. View

10.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

11.

Thakur P, Shrivastava R, Shrivastava V . Oxytocin as a Potential Adjuvant Against COVID-19 Infection. Endocr Metab Immune Disord Drug Targets. 2020; 21(7):1155-1162. DOI: 10.2174/1871530320666200910114259. View

12.

Schwerbrock N, Karlsson E, Shi Q, Sheridan P, Beck M . Fish oil-fed mice have impaired resistance to influenza infection. J Nutr. 2009; 139(8):1588-94. PMC: 2709305. DOI: 10.3945/jn.109.108027. View

13.

Eiland L, McEwen B . Early life stress followed by subsequent adult chronic stress potentiates anxiety and blunts hippocampal structural remodeling. Hippocampus. 2010; 22(1):82-91. DOI: 10.1002/hipo.20862. View

14.

Liu X, Long C, Xiong Q, Chen C, Ma J, Su Y . Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis. Clin Cardiol. 2020; . PMC: 7436520. DOI: 10.1002/clc.23421. View

15.

Trojan E, Chamera K, Bryniarska N, Kotarska K, Leskiewicz M, Regulska M . Role of Chronic Administration of Antidepressant Drugs in the Prenatal Stress-Evoked Inflammatory Response in the Brain of Adult Offspring Rats: Involvement of the NLRP3 Inflammasome-Related Pathway. Mol Neurobiol. 2019; 56(8):5365-5380. PMC: 6614144. DOI: 10.1007/s12035-018-1458-1. View

16.

Felger J, Miller A . Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol. 2012; 33(3):315-27. PMC: 3484236. DOI: 10.1016/j.yfrne.2012.09.003. View

17.

Makola R, Mbazima V, Mokgotho M, Gallicchio V, Matsebatlela T . The Effect of Lithium on Inflammation-Associated Genes in Lipopolysaccharide-Activated Raw 264.7 Macrophages. Int J Inflam. 2020; 2020:8340195. PMC: 7397420. DOI: 10.1155/2020/8340195. View

18.

de Sa Lima L, Kawamoto E, Munhoz C, Kinoshita P, Orellana A, Curi R . Ouabain activates NFκB through an NMDA signaling pathway in cultured cerebellar cells. Neuropharmacology. 2013; 73:327-36. DOI: 10.1016/j.neuropharm.2013.06.006. View

19.

De Kock M, Loix S, Lavandhomme P . Ketamine and peripheral inflammation. CNS Neurosci Ther. 2013; 19(6):403-10. PMC: 6493703. DOI: 10.1111/cns.12104. View

20.

Lenze E, Mattar C, Zorumski C, Stevens A, Schweiger J, Nicol G . Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(22):2292-2300. PMC: 7662481. DOI: 10.1001/jama.2020.22760. View